作者
Min He,Shuang Hao,Linxiaoxi Ma,Bingqiu Xiu,Benlong Yang,Zehao Wang,Jingyan Xue,Yayun Chi,Min Xiong,JiaJian Chen,Xiaoyan Huang,XiYu Liu,Songyang Wu,Qin Xiao,Yan Huang,Ruohong Shui,A‐Yong Cao,Junjie Li,Gen‐Hong Di,Wentao Yang,Xin Hu,Guang-Yu Liu,Ke‐Da Yu,Yi‐Zhou Jiang,Zhonghua Wang,Zhi‐Ming Shao,Jiong Wu
摘要
Toripalimab, a novel PD-1 antibody, is approved for treatment of multiple solid tumors; however, its neoadjuvant use with chemotherapy for triple-negative breast cancer (TNBC) remains unevaluated. Additionally, induction chemotherapy followed by de-escalation of neoadjuvant immunotherapy remains underexplored. Therefore, we conducted a phase II trial investigating a novel neoadjuvant chemoimmunotherapy regimen including de-escalation of immunotherapy for early-stage TNBC.